China The collaboration between BioNTech and Pfizer on a COVID-19 vaccine candidate based on mRNA technology continues apace, with hopes for an emergency approval in late-2019. In China, home to 1.4 billion people, BioNTech is leveraging the expertise of domestic firm Fosun Pharma for trials and commercialisation of another vaccine candidate,…
Roundup Recent news from the cross-border deals and partnerships being struck by Chinese pharmacos, including I-Mab’s USD 2 billion immuno-oncology collaboration with AbbVie, Jiangsu Hengrui’s latest deal with US biotech Dyadic, and Fosun Pharma’s role in the Pfizer/BioNTech COVID-19 vaccine. AbbVie and Chinese biotech I-Mab Enter Into Global Strategic Partnership…
China China’s regulator approved a biosimilar version of Roche’s Rituxan this week, the first such drug ever to be given the green light in the country. With numerous other biological copycats of blockbuster drugs in development, potentially difficult times lie ahead for Roche and other Big Pharma firms in China. …
China Chen Qiyu, chairman of Fosun Pharma, discusses how the company is helping China achieve its ‘Healthy China 2020’ goals as well as its unique business model and company culture. Fosun Pharma is an integrated pharmaceutical company with interests all along the value chain, from API to finished products, distribution, medical…
See our Cookie Privacy Policy Here
